Safety Through Genomics

Premium

"Warning," blares the voice on the television. "This drug may cause drowsiness, dizziness, blurred vision, rapid heartbeat, shortness of breath, upset stomach, hallucinations, loss of sexual function, or death. Do not take if you are pregnant or plan to become pregnant." Sound familiar? Ads for antidepressants warn of the possible risk of suicidal thoughts, while commercials for erectile dysfunction medications notify users of the possibility for uncomfortably prolonged erections. Caveats like these should be recognizable to anyone who has ever taken so much as an aspirin.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Browse our free articles
You can still register for access to our free content.

In Nature this week: genomic analysis of high-grade serous ovarian cancer, and more.

The new Riken president outlines some of his plans for the institute.

The Guardian discusses whether big science projects are worth the loss of resources available for other scientific pursuits.

An NEJM update from the ClinVar team highlights the difficulties of interpreting genetic variants.